Venture capital firm set to reap rewards on swine flu


Alexander Haislip
Sunday, April 26, 2009

The swine flu outbreak is likely to benefit one of the most prolific and successful venture capital firms in the United States: Kleiner Perkins Caufield & Byers, Thomson Reuters Private Equity Week reported on Friday.

Shares of the two public companies in the firm’s portfolio of eight Pandemic and Bio Defense companies — BioCryst Pharmaceuticals (BCRX.O) and Novavax (NVAX.O) — jumped Friday on news that the swine flu killed a reported 60 people in Mexico and has infected people in the United States.

The World Health Organization said the virus appears to be susceptible to Roche’s (ROG.VX) flu drug Tamiflu, also known as oseltamivir, but not to older flu drugs such as amantadine.

Shares of Swiss drugmaker Roche Holding AG closed up 3.48 percent after falling sharply earlier in the week on a cancer drug disappointment, while shares of U.S. biotechnology company Gilead Sciences Inc (GILD.O), which gets royalties from Roche on Tamiflu sales, slipped 10 cents to $45.80 on Friday.

For the rest of the article go here.

Clare Swinney

Next Post

How to Protect Yourself From Biological Warfare

Mon Apr 27 , 2009
It is time to post this again.  It has been updated since it was first posted on this site.  Go here for links to Femacamper’s site to see the original article. Femacamper has lived in three countries where there were outbreaks and he knows of people who have used it […]